Skip to main content
PMC home page
Annals of Surgery logoLink to Annals of Surgery
. 1997 Dec;226(6):688–703. doi: 10.1097/00000658-199712000-00006

Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis.

P E Majno 1, R Adam 1, H Bismuth 1, D Castaing 1, A Ariche 1, J Krissat 1, H Perrin 1, D Azoulay 1
PMCID: PMC1191140  PMID: 9409568

Abstract

OBJECTIVE: To investigate the impact of preoperative transarterial lipiodol chemoembolization (TACE) in the management of patients undergoing liver resection or liver transplantation for hepatocellular carcinoma. PATIENTS AND METHODS: TACE was performed before surgery in 49 of 76 patients undergoing resection and in 54 of 111 patients undergoing liver transplantation. Results were retrospectively analyzed with regard to the response to treatment, the type of procedure performed, the incidence of complications, the incidence and pattern of recurrence, and survival. RESULTS: In liver resection, downstaging of the tumor by TACE (21 of 49 patients [42%]) and total necrosis (24 of 49 patients [50%]) were associated with a better disease-free survival than either no response to TACE or no TACE (downstaging, 29% vs. 10% and 11 % at 5 years, p = 0.08 and 0.10; necrosis, 22% vs. 13% and 11% at 5 years, p = 0.1 and 0.3). Five patients (10%) with previously unresectable tumors could be resected after downstaging. In liver transplantation, downstaging of tumors >3 cm (19 of 35 patients [54%]) and total necrosis (15 of 54 patients [28%]) were associated with better disease-free survival than either incomplete response to TACE or no TACE (downstaging, 71 % vs. 29% and 49% at 5 years, p = 0.01 and 0.09; necrosis, 87% vs. 47% and 60% at 5 years, p = 0.03 and 0.14). Multivariate analysis of the factors associated with response to TACE showed that downstaging occurred more frequently for tumors >5 cm. CONCLUSIONS: Downstaging or total necrosis of the tumor induced by TACE occurred in 62% of the cases and was associated with improved disease-free survival both after liver resection and transplantation. In liver resection, TACE was also useful to improve the resectability of primarily unresectable tumors. In liver transplantation, downstaging in patients with tumors >3 cm was associated with survival similar to that in patients with less extensive disease.

Full text

PDF
688

Images in this article

698Figure 7.
on p.698
699Figure 8.
on p.699

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adachi E., Matsumata T., Nishizaki T., Hashimoto H., Tsuneyoshi M., Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer. 1993 Dec 15;72(12):3593–3598. doi: 10.1002/1097-0142(19931215)72:12<3593::aid-cncr2820721208>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  2. Adam R., Akpinar E., Johann M., Kunstlinger F., Majno P., Bismuth H. Place of cryosurgery in the treatment of malignant liver tumors. Ann Surg. 1997 Jan;225(1):39–50. doi: 10.1097/00000658-199701000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Akashi Y., Koreeda C., Enomoto S., Uchiyama S., Mizuno T., Shiozaki Y., Sameshima Y., Inoue K. Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology. 1991 Aug;14(2):262–268. [PubMed] [Google Scholar]
  4. Azoulay D., Raccuia J. S., Castaing D., Bismuth H. Right portal vein embolization in preparation for major hepatic resection. J Am Coll Surg. 1995 Sep;181(3):266–269. [PubMed] [Google Scholar]
  5. Bismuth H., Adam R., Lévi F., Farabos C., Waechter F., Castaing D., Majno P., Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996 Oct;224(4):509–522. doi: 10.1097/00000658-199610000-00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bismuth H., Adam R., Mathur S., Sherlock D. Options for elective treatment of portal hypertension in cirrhotic patients in the transplantation era. Am J Surg. 1990 Jul;160(1):105–110. doi: 10.1016/s0002-9610(05)80878-5. [DOI] [PubMed] [Google Scholar]
  7. Bismuth H., Chiche L., Adam R., Castaing D., Diamond T., Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993 Aug;218(2):145–151. doi: 10.1097/00000658-199308000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bismuth H., Houssin D., Castaing D. Major and minor segmentectomies "réglées" in liver surgery. World J Surg. 1982 Jan;6(1):10–24. doi: 10.1007/BF01656369. [DOI] [PubMed] [Google Scholar]
  9. Bismuth H., Houssin D., Ornowski J., Meriggi F. Liver resections in cirrhotic patients: a Western experience. World J Surg. 1986 Apr;10(2):311–317. doi: 10.1007/BF01658152. [DOI] [PubMed] [Google Scholar]
  10. Bismuth H., Morino M., Sherlock D., Castaing D., Miglietta C., Cauquil P., Roche A. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg. 1992 Apr;163(4):387–394. doi: 10.1016/0002-9610(92)90039-t. [DOI] [PubMed] [Google Scholar]
  11. Calne R., Yamanoi A., Oura S., Kawamura M. Liver transplantation for hepatocarcinoma. Surg Today. 1993;23(1):1–3. doi: 10.1007/BF00308991. [DOI] [PubMed] [Google Scholar]
  12. Choi B. I., Park J. H., Kim B. H., Kim S. H., Han M. C., Kim C. W. Small hepatocellular carcinoma: detection with sonography, computed tomography (CT), angiography and Lipiodol-CT. Br J Radiol. 1989 Oct;62(742):897–903. doi: 10.1259/0007-1285-62-742-897. [DOI] [PubMed] [Google Scholar]
  13. Ganne-Carrié N., Chastang C., Chapel F., Munz C., Pateron D., Sibony M., Dény P., Trinchet J. C., Callard P., Guettier C. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology. 1996 May;23(5):1112–1118. doi: 10.1002/hep.510230527. [DOI] [PubMed] [Google Scholar]
  14. Harada T., Matsuo K., Inoue T., Tamesue S., Inoue T., Nakamura H. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg. 1996 Jul;224(1):4–9. doi: 10.1097/00000658-199607000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ikeda K., Kumada H., Saitoh S., Arase Y., Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer. 1991 Nov 15;68(10):2150–2154. doi: 10.1002/1097-0142(19911115)68:10<2150::aid-cncr2820681011>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  16. Ismail T., Angrisani L., Gunson B. K., Hübscher S. G., Buckels J. A., Neuberger J. M., Elias E., McMaster P. Primary hepatic malignancy: the role of liver transplantation. Br J Surg. 1990 Sep;77(9):983–987. doi: 10.1002/bjs.1800770908. [DOI] [PubMed] [Google Scholar]
  17. Iwatsuki S., Starzl T. E., Sheahan D. G., Yokoyama I., Demetris A. J., Todo S., Tzakis A. G., Van Thiel D. H., Carr B., Selby R. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991 Sep;214(3):221–229. doi: 10.1097/00000658-199109000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Izumi R., Shimizu K., Iyobe T., Ii T., Yagi M., Matsui O., Nonomura A., Miyazaki I. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology. 1994 Aug;20(2):295–301. [PubMed] [Google Scholar]
  19. Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M., Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989 Oct;97(4):965–971. doi: 10.1016/0016-5085(89)91505-9. [DOI] [PubMed] [Google Scholar]
  20. Liou T. C., Shih S. C., Kao C. R., Chou S. Y., Lin S. C., Wang H. Y. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization. J Hepatol. 1995 Nov;23(5):563–568. doi: 10.1016/0168-8278(95)80063-8. [DOI] [PubMed] [Google Scholar]
  21. Lipiodol computed tomography for small hepatocellular carcinomas. Lancet. 1991 Feb 9;337(8737):333–334. [PubMed] [Google Scholar]
  22. Madden M. V., Krige J. E., Bailey S., Beningfield S. J., Geddes C., Werner I. D., Terblanche J. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 1993 Nov;34(11):1598–1600. doi: 10.1136/gut.34.11.1598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693–699. doi: 10.1056/NEJM199603143341104. [DOI] [PubMed] [Google Scholar]
  24. McPeake J. R., O'Grady J. G., Zaman S., Portmann B., Wight D. G., Tan K. C., Calne R. Y., Williams R. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol. 1993 Jun;18(2):226–234. doi: 10.1016/s0168-8278(05)80250-8. [DOI] [PubMed] [Google Scholar]
  25. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  26. Mondazzi L., Bottelli R., Brambilla G., Rampoldi A., Rezakovic I., Zavaglia C., Alberti A., Idèo G. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994 May;19(5):1115–1123. [PubMed] [Google Scholar]
  27. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K. T., Tanaka T., Tsurumi K., Okuno M., Tomita E. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996 Jun 13;334(24):1561–1567. doi: 10.1056/NEJM199606133342402. [DOI] [PubMed] [Google Scholar]
  28. Nagasue N., Galizia G., Kohno H., Chang Y. C., Hayashi T., Yamanoi A., Nakamura T., Yukaya H. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery. 1989 Jul;106(1):81–86. [PubMed] [Google Scholar]
  29. O'Grady J. G., Polson R. J., Rolles K., Calne R. Y., Williams R. Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg. 1988 Apr;207(4):373–379. doi: 10.1097/00000658-198804000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pelletier G., Roche A., Ink O., Anciaux M. L., Derhy S., Rougier P., Lenoir C., Attali P., Etienne J. P. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990 Sep;11(2):181–184. doi: 10.1016/0168-8278(90)90110-d. [DOI] [PubMed] [Google Scholar]
  31. Ringe B., Pichlmayr R., Wittekind C., Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991 Mar-Apr;15(2):270–285. doi: 10.1007/BF01659064. [DOI] [PubMed] [Google Scholar]
  32. Ryder S. D., Rizzi P. M., Metivier E., Karani J., Williams R. Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma. Gut. 1996 Jan;38(1):125–128. doi: 10.1136/gut.38.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Selby R., Kadry Z., Carr B., Tzakis A., Madariaga J. R., Iwatsuki S. Liver transplantation for hepatocellular carcinoma. World J Surg. 1995 Jan-Feb;19(1):53–58. doi: 10.1007/BF00316980. [DOI] [PubMed] [Google Scholar]
  34. Sheu J. C., Sung J. L., Chen D. S., Yang P. M., Lai M. Y., Lee C. S., Hsu H. C., Chuang C. N., Yang P. C., Wang T. H. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology. 1985 Aug;89(2):259–266. doi: 10.1016/0016-5085(85)90324-5. [DOI] [PubMed] [Google Scholar]
  35. Shimamura Y., Gunvén P., Takenaka Y., Shimizu H., Akimoto H., Shima Y., Arima K., Takahashi A., Kitaya T., Matsuyama T. Selective portal branch occlusion by balloon catheter during liver resection. Surgery. 1986 Nov;100(5):938–941. [PubMed] [Google Scholar]
  36. Spreafico C., Marchianò A., Regalia E., Frigerio L. F., Garbagnati F., Andreola S., Milella M., Lanocita R., Mazzaferro V. Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology. 1994 Sep;192(3):687–690. doi: 10.1148/radiology.192.3.8058934. [DOI] [PubMed] [Google Scholar]
  37. Takenaka K., Yoshida K., Nishizaki T., Korenaga D., Hiroshige K., Ikeda T., Sugimachi K. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg. 1995 Apr;169(4):400–405. doi: 10.1016/s0002-9610(99)80184-6. [DOI] [PubMed] [Google Scholar]
  38. Uchida M., Kohno H., Kubota H., Hayashi T., Yamanoi A., Kimoto T., Ono T., Nagasue N. Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg. 1996 Mar-Apr;20(3):326–331. doi: 10.1007/s002689900052. [DOI] [PubMed] [Google Scholar]
  39. Van Thiel D. H., Carr B., Iwatsuki S., Selby R. R., Fung J. J., Starzl T. E. The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991. J Surg Oncol Suppl. 1993;3:78–82. doi: 10.1002/jso.2930530522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Vetter D., Wenger J. J., Bergier J. M., Doffoel M., Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology. 1991 Mar;13(3):427–433. [PubMed] [Google Scholar]
  41. Wu C. C., Ho Y. Z., Ho W. L., Wu T. C., Liu T. J., P'eng F. K. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg. 1995 Jan;82(1):122–126. doi: 10.1002/bjs.1800820141. [DOI] [PubMed] [Google Scholar]
  42. Yamada R., Sato M., Kawabata M., Nakatsuka H., Nakamura K., Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983 Aug;148(2):397–401. doi: 10.1148/radiology.148.2.6306721. [DOI] [PubMed] [Google Scholar]
  43. Yamashita Y., Takahashi M., Koga Y., Saito R., Nanakawa S., Hatanaka Y., Sato N., Nakashima K., Urata J., Yoshizumi K. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer. 1991 Jan 15;67(2):385–391. doi: 10.1002/1097-0142(19910115)67:2<385::aid-cncr2820670212>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  44. Yu Y. Q., Xu D. B., Zhou X. D., Lu J. Z., Tang Z. Y., Mack P. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer. 1993 Jan 1;71(1):62–65. doi: 10.1002/1097-0142(19930101)71:1<62::aid-cncr2820710111>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  45. Yuki K., Hirohashi S., Sakamoto M., Kanai T., Shimosato Y. Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases. Cancer. 1990 Nov 15;66(10):2174–2179. doi: 10.1002/1097-0142(19901115)66:10<2174::aid-cncr2820661022>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  46. Yumoto Y., Jinno K., Tokuyama K., Araki Y., Ishimitsu T., Maeda H., Konno T., Iwamoto S., Ohnishi K., Okuda K. Hepatocellular carcinoma detected by iodized oil. Radiology. 1985 Jan;154(1):19–24. doi: 10.1148/radiology.154.1.2981112. [DOI] [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES